Progyny, Inc. (PGNY) Spending and interest coverage
- R&D / revenue · 12 months: Value 0.90%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.18%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 0.90% | Research and development expense / revenue. Period ending 2026-06-30. $11.80M ÷ $1.31B × 100 ≈ 0.90% |
| Stock-based compensation / revenue · 12 months | 8.18% | Share-based compensation / revenue. Period ending 2026-06-30. $107.17M ÷ $1.31B × 100 ≈ 8.18% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 11.80M USD | Research and Development Expense |
| Revenue | 1.31B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 107.17M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 112.13M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.80M | $1.31B | $107.17M | $112.13M | (m) | 0.90% | 8.18% | (m) | (m) |
| 2026-03-31 | $10.80M | $1.29B | $119.08M | $96.49M | (m) | 0.84% | 9.21% | (m) | (m) |
| 2025-12-31 | $9.50M | $1.29B | $131.87M | $85.28M | (m) | 0.74% | 10.23% | (m) | (m) |
| 2025-09-30 | (m) | $1.27B | $127.93M | $85.84M | (m) | (m) | 10.08% | (m) | (m) |
| 2025-06-30 | (m) | $1.24B | $128.94M | $76.77M | (m) | (m) | 10.38% | (m) | (m) |
| 2025-03-31 | (m) | $1.21B | $129.59M | $73.10M | (m) | (m) | 10.68% | (m) | (m) |
| 2024-12-31 | (m) | $1.17B | $128.13M | $67.45M | (m) | (m) | 10.98% | (m) | (m) |
| 2024-09-30 | (m) | (m) | $126.07M | $65.47M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $124.14M | $71.20M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $122.86M | $65.70M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.09B | $122.61M | $62.18M | (m) | (m) | 11.26% | (m) | (m) |
| 2023-09-30 | (m) | (m) | $123.11M | $51.69M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $115.16M | $44.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $107.06M | $38.41M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $786.91M | $100.75M | $23.34M | (m) | (m) | 12.80% | (m) | (m) |
| 2022-09-30 | (m) | (m) | $86.46M | $19.85M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $70.31M | $17.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $53.17M | $20.48M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $33.71M | $32.34M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $22.86M | $33.69M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $18.78M | $29.45M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $15.81M | $16.72M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $12.82M | $8.35M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $10.51M | $8.54M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $9.12M | $6.25M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $6.59M | $10.43M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $5.06M | $9.68M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | $4.17M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | $1.50M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $3.00M | $-3.45M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $1.56M | $-11.01M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |